



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Chang

Application No. 09/826,115

Filed: April 4, 2001

For: NUCLEIC ACID VACCINES FOR  
PREVENTION OF FLAVIVIRUS INFECTION

Examiner: Not yet known

Date: April 11, 2003

Art Unit: 1642

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service on April 11, 2003 as First Class Mail in an envelope addressed to: COMMISSIONER FOR PATENTS, WASHINGTON, D.C. 20231.

Tanya M. Harding, Ph.D.  
Attorney for Applicant

INFORMATION DISCLOSURE STATEMENT  
PURSUANT TO 37 C.F.R. § 1.97(b)(3)COMMISSIONER FOR PATENTS  
WASHINGTON, DC 20231

Listed on the accompanying form PTO-1449 and enclosed herewith are several English-language documents. Applicant respectfully requests that these documents be listed as references cited on the issued patent.

Applicant filed this Information Disclosure Statement ("IDS") before the mailing date of a first Office action on the merits. As a result, no fee should be required to file this IDS. However, if the Patent Office determines that a fee is required for Applicant to file this Information Disclosure Statement, please see the attached transmittal letter for deposit account authority.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By

Tanya M. Harding, Ph.D.  
Registration No. 42,630

One World Trade Center, Suite 1600  
121 S.W. Salmon Street  
Portland, Oregon 97204  
Telephone: (503) 226-7391  
Facsimile: (503) 228-9446

*See Only*  
07/28/2004 DMARTIND 00000019 024550 09826115  
01 FC:1806 180.00 DA